Related Experiment Video
Updated: Mar 26, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy
Shraddha Narechania1, Nirosshan Thiruchelvam2, Chetan Lokhande3
1Department of Internal Medicine, Fairview Hospital, Cleveland, Ohio, USA. narechs@ccf.org.
Abstract:
Zoledronic acid is a parenteral long-acting bisphosphonate that has been shown to be more effective than other bisphosphonates in treating hypercalcemia of malignancy. It is important to be aware of its ability to induce prolonged and severe hypocalcemia (hypoCa) following administration, which can be difficult to control despite aggressive calcium replacement. We report on a patient with metastatic breast cancer who presented with severe symptomatic hypoCa after receiving zoledronic acid for hypercalcemia of malignancy.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Skeleton and Calcium Homeostasis
Bone Remodeling
Chronic Kidney Disease II: Clinical Manifestations
Osteoclasts in Bone Remodeling
